Alopecia Areata Trial, Recruiting (NCT07422376)

Alopecia Areata Trial, Recruiting NCT07422376 Sponsor: Charles Mays Condition: Alopecia Areata

Printed from Voxsanity (voxsanity.com.au) — NCT07422376 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Alopecia Areata

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

You have been diagnosed with stage I, II, or III breast cancer
You are aged 18 years or older
You are planned to receive chemotherapy that includes a type of drug called an anthracycline or a taxane
You are willing and able to give your consent to take part (participation is completely voluntary and your care will not be affected if you choose not to join)

Who may not be able to join:

Your breast cancer has spread to other parts of the body (stage IV)
You are planning to shave your head completely during chemotherapy (trimming or cutting your hair is allowed, as long as it does not interfere with measuring hair thickness)
You have a condition or situation that means you cannot safely use the PAXMAN Scalp Cooling System — this includes certain blood cancers, a cold-related skin allergy (cold urticaria), a blood condition called cold agglutinin disease, cancer that has spread to the scalp, certain very intensive chemotherapy treatments, or planned radiation to the skull (confirm with trial site)
You have sores, wounds, or pain on your scalp that could be made worse by wearing a scalp cooling cap

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 27 July 2026

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Phone: 4234315654

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT07422376

Sponsor: Charles Mays

Phase: Not Applicable

Status: Recruiting

Condition: Alopecia Areata

Trial contact: 4234315654

More information: https://clinicaltrials.gov/study/NCT07422376

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

You have been diagnosed with stage I, II, or III breast cancer
You are aged 18 years or older
You are planned to receive chemotherapy that includes a type of drug called an anthracycline or a taxane
You are willing and able to give your consent to take part (participation is completely voluntary and your care will not be affected if you choose not to join)

Who may not be able to join:

Your breast cancer has spread to other parts of the body (stage IV)
You are planning to shave your head completely during chemotherapy (trimming or cutting your hair is allowed, as long as it does not interfere with measuring hair thickness)
You have a condition or situation that means you cannot safely use the PAXMAN Scalp Cooling System — this includes certain blood cancers, a cold-related skin allergy (cold urticaria), a blood condition called cold agglutinin disease, cancer that has spread to the scalp, certain very intensive chemotherapy treatments, or planned radiation to the skull (confirm with trial site)
You have sores, wounds, or pain on your scalp that could be made worse by wearing a scalp cooling cap

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 27 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Not Applicable

Sponsor

Charles Mays

Registry

ClinicalTrials.gov

Start date

1 March 2026

Est. completion

1 January 2027

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Hair Retention and Regrowth; Hair Retention and Chemotherapy-Induced Alopecia Distress

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov